February 2025
1. WATANABE T, Tokumoto Y, Ochi H, Mashiba T, et al
   Clinical factors to predict changes of esophagogastric varices after sustained viral response with direct-acting antiviral therapy.
   J Gastroenterol. 2025;60:222-234.
   

   >> Share

   
   November 2024
2. IWAMOTO T, Nozaki Y, Inoue T, Suda T, et al
   Histological improvement of fibrosis in patients with hepatitis C who achieved a 5-year sustained virological response to treatment with direct-acting antivirals.
   J Gastroenterol. 2024 Nov 25. doi: 10.1007/s00535-024-02165.
   

   >> Share

   
   September 2024
3. YAMAUCHI K, Maekawa S, Osawa L, Komiyama Y, et al
   Single-molecule sequencing of the whole HCV genome revealed envelope deletions in decompensated cirrhosis associated with NS2 and NS5A mutations.
   J Gastroenterol. 2024 Sep 3. doi: 10.1007/s00535-024-02146.
   

   >> Share

   
   May 2024
4. SUZUKI T, Matsuura K, Nagura Y, Ito K, et al
   MicroRNA-223-3p levels in serum-derived extracellular vesicles predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents.
   J Gastroenterol. 2024 May 13. doi: 10.1007/s00535-024-02115.
   

   >> Share

   
   
5. ATSUKAWA M, Tsubota A, Kondo C, Toyoda H, et al
   ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.
   J Gastroenterol. 2024 May 10. doi: 10.1007/s00535-024-02109.
   

   >> Share

   
   April 2024
6. LIU CH, Chang YP, Fang YJ, Cheng PN, et al
   Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals.
   J Gastroenterol. 2024 Apr 13. doi: 10.1007/s00535-024-02101.
   

   >> Share

   
   December 2023
7. UOJIMA H, Nakabayashi K, Yamasaki K, Sugiyama M, et al
   New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease.
   J Gastroenterol. 2023;58:1252-1260.
   

   >> Share

   
   October 2023
8. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
   Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
   J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
   

   >> Share

   
   March 2023
9. SHIMAKAMI T, Setoyama H, Oza N, Itakura J, et al
   Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan.
   J Gastroenterol. 2023;58:257-267.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share